TY - JOUR
T1 - Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow study
AU - Verbeek, Martijn W.C.
AU - Buracchi, Chiara
AU - Laqua, Anna
AU - Nierkens, Stefan
AU - Sedek, Lukasz
AU - Flores-Montero, Juan
AU - Hofmans, Mattias
AU - Sobral de Costa, Elaine
AU - Nováková, Michaela
AU - Mejstrikova, Ester
AU - Barrena, Susana
AU - Kohlscheen, Saskia
AU - Szczepanowski, Monika
AU - Kulis, Jan
AU - Oliveira, Elen
AU - Jugooa, Romana
AU - de Jong, Anja X.
AU - Szczepanski, Tomasz
AU - Philippé, Jan
AU - van Dongen, Jacques J.M.
AU - Orfao, Alberto
AU - Brüggemann, Monika
AU - Gaipa, Giuseppe
AU - van der Velden, Vincent H.J.
N1 - Funding Information:
JJMvD, AO, JFM, TS and VHJvdV each report being one of the inventors on the EuroFlow‐owned patent PCT/NL2010/050332 (Methods, reagents and kits for flow cytometric immunophenotyping of normal, reactive and malignant leukocytes). The Infinicyt software is based on intellectual property of some EuroFlow laboratories (University of Salamanca in Spain and Federal University of Rio de Janeiro in Brazil) and the scientific input of other EuroFlow members. All above‐mentioned intellectual property and related patents are licensed to Cytognos (Salamanca, Spain) and BD Biosciences (San José, CA, USA), which companies pay royalties to the EuroFlow Consortium. These royalties are exclusively used for continuation of the EuroFlow collaboration and sustainability of the EuroFlow consortium. VHJvdV reports a Laboratory Services Agreement with BD Biosciences; all related fees are for the Erasmus MC. JJMvD and JAOMCV report an Educational Services Agreement from BD Biosciences and a Scientific Advisor Agreement with Cytognos; all related fees and honoraria are for the involved university departments at Leiden University Medical Centre and University of Salamanca. MB received personal fees from Incyte (advisory board) and Roche Pharma AG, financial support for reference diagnostics from Affimed, Amgen, BMS and Regeneron, grants and personal fees from Amgen (advisory board, speakers bureau, travel support), and personal fees from Janssen (speakers bureau), all outside the submitted work. The other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher Copyright:
© 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
PY - 2022/4
Y1 - 2022/4
N2 - The standardized EuroFlow protocol, including CD19 as primary B-cell marker, enables highly sensitive and reliable minimal residual disease (MRD) assessment in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) patients treated with chemotherapy. We developed and validated an alternative gating strategy allowing reliable MRD analysis in BCP-ALL patients treated with CD19-targeting therapies. Concordant data were obtained in 92% of targeted therapy patients who remained CD19-positive, whereas this was 81% in patients that became (partially) CD19-negative. Nevertheless, in both groups median MRD values showed excellent correlation with the original MRD data, indicating that, despite higher interlaboratory variation, the overall MRD analysis was correct.
AB - The standardized EuroFlow protocol, including CD19 as primary B-cell marker, enables highly sensitive and reliable minimal residual disease (MRD) assessment in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) patients treated with chemotherapy. We developed and validated an alternative gating strategy allowing reliable MRD analysis in BCP-ALL patients treated with CD19-targeting therapies. Concordant data were obtained in 92% of targeted therapy patients who remained CD19-positive, whereas this was 81% in patients that became (partially) CD19-negative. Nevertheless, in both groups median MRD values showed excellent correlation with the original MRD data, indicating that, despite higher interlaboratory variation, the overall MRD analysis was correct.
KW - acute leukaemia
KW - diagnostic haematology
KW - flow cytometry
KW - minimal residual disease
KW - Neoplasm, Residual
KW - Adaptor Proteins, Signal Transducing
KW - Antigens, CD19/therapeutic use
KW - Humans
KW - Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/diagnosis
KW - Flow Cytometry/methods
KW - Burkitt Lymphoma
KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma
UR - https://www.scopus.com/pages/publications/85120974952
U2 - 10.1111/bjh.17992
DO - 10.1111/bjh.17992
M3 - Article
C2 - 34881427
AN - SCOPUS:85120974952
SN - 0007-1048
VL - 197
SP - 76
EP - 81
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 1
ER -